WO 2005/026155 PCT/EP2004/052137

- 111 -

Claims

1. A benzimidazole acetonitrile according to formula (I)

$$\begin{array}{c|c}
R^2 \\
N \\
CN \\
G-L
\end{array}$$
(1)

5

as well as its tautomers, its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof, wherein

G is a pyrimidinyl;

L is an amino group, or a 3-8 membered heterocycloalkyl, containing at least one heteroatom selected from N, O, S or L is an acylamino moiety;

R¹ is selected from the group comprising or consisting of hydrogen, sulfonyl, amino, carboxy, amino carbonyl, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl or C₁-C₆-alkoxy, aryl, halogen, cyano or hydroxy;

15 R² is selected from the group comprising or consisting of hydrogen, C₁-C₆-alkyl, C₂-C₆-alkynyl, or C₁-C₆-alkoxy.

- 2. The benzimidazole acetonitrile according to claim 1, wherein R^1 is H or C_1 - C_3 alkyl.
- 3. The benzimidazole acetonitrile according to any of claims 1 or 2, wherein R^2 is a C_1 - C_3 alkyl.

4. The benzimidazole acetonitrile according to any of claims 1 to 3, having any of the formulae

wherein R1 is as above defined, and

R³ is selected from the group comprising or consisting of hydrogen, C₁-C₆-alkyl, C₂-C₆-alkynyl, or C₁-C₆-alkoxy;

L is an amino group of the formula $-NR^5R^6$ wherein R^5 and R^6 are each independently from each other H, C_1 - C_6 -alkyl, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, C_1 - C_6 -alkoxy, aryl, heteroaryl, saturated or unsaturated 3-8-membered cycloalkyl, 3-8-membered heterocycloalkyl, C_1 - C_6 -alkyl aryl, C_1 - C_6 -alkyl heteroaryl, C_1 - C_6 -alkenyl aryl, C_1 - C_6 -alkenyl heteroaryl, C_1 - C_6 -alkynyl aryl, C_1 - C_6 -alkynyl heteroaryl, C_1 - C_6 -alkyl cycloalkyl, C_1 - C_6 -alkyl heterocycloalkyl, C_1 - C_6 -alkenyl cycloalkyl, C_1 - C_6 -alkenyl heterocycloalkyl, C_1 - C_6 -alkynyl heterocycloalkyl, $C_$

- R^5 and R^6 may form a ring together with the nitrogen to which they are bound.
 - 5. The benzimidazole acetonitrile according to any of the preceding claims, wherein R⁵ is hydrogen or a methyl or ethyl or propyl group and R⁶ is a selected from the group consisting of H, (C₁-C₁₀)-alkyl, C₁-C₆ alkyl-aryl, C₁-C₆-alkyl-heteroaryl, cycloalkyl,

- heterocycloalkyl, aryl or heteroaryl and 4-8 membered saturated or unsaturated cycloalkyl.
- 6. The benzimidazole acetonitrile according to any of the preceding claims, wherein R⁵ is H and R⁶ is selected from the group consisting of C₁-C₆ alkyl, 3-8 membered cycloalkyl, 3-8 membered heterocycloalkyl, heteroaryl, C₁-C₆-alkyl heteroaryl, C₁-C₆-alkyl cycloalkyl, C₁-C₆-alkyl heterocycloalkyl.

20

- 7. The benzoxazole acetonitrile according to any of claims 1 to 3, wherein L is an acylamino moiety of the formula –NR⁵C(O)R⁶ wherein R⁵ and R⁶ are each independently from each other H, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₁-C₆-alkynyl, aryl, heteroaryl, saturated or unsaturated 3-8-membered cycloalkyl, 3-8-membered heterocycloalkyl, C₁-C₆-alkyl aryl, C₁-C₆-alkyl heteroaryl, C₁-C₆-alkenyl aryl, C₁-C₆-alkynyl heteroaryl, C₁-C₆-alkyl heterocycloalkyl, C₁-C₆-alkynyl cycloalkyl, C₁-C₆-alkynyl heterocycloalkyl, C₁-C₆-alkynyl heterocycloalkyl, C₁-C₆-alkynyl heterocycloalkyl.
- 15 8. The benzimidazole acetonitrile according to any of the preceding claims selected from the group consisting of:
 - (2Z)-(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)(2-{[3-(1H-pyrazol-1-yl)propyl]amino}pyrimidin-4-yl)acetonitrile
 - (2Z)-(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)(5-methyl-2-{[3-(1H-pyrazol-1-yl)propyl]amino}pyrimidin-4-yl)acetonitrile
 - (2Z)-[2-(cyclobutylamino)-5-methylpyrimidin-4-yl](1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)acetonitrile
 - (2Z)-(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)(5-methyl-2-{[3-(2-oxopyrrolidin-1-yl)propyl]amino}pyrimidin-4-yl)acetonitrile

- 114 -

- (2Z)-(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)(2-{[3-(2-oxopyrrolidin-1-yl)propyl]amino}pyrimidin-4-yl)acetonitrile
- (2Z)-(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)(2-{[3-(1H-1,2,4-triazol-1-yl)propyl]amino}pyrimidin-4-yl)acetonitrile
- 5 (2Z)-(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)(5-methyl-2-{[3-(1H-1,2,4-triazol-1-yl)propyl]amino}pyrimidin-4-yl)acetonitrile
 - [2-(cyclopentylamino)-5-methylpyrimidin-4-yl](1-ethyl-1H-benzimidazol-2-yl)acetonitrile
- (2Z)-(2-{[3-(2-oxopyrrolidin-1-yl)propyl]amino}pyrimidin-4-yl)(1-propyl-1,3-dihydro-2H-benzimidazol-2-ylidene)acetonitrile
 - (1-ethyl-1H-benzimidazol-2-yl) {5-methyl-2-[(2-pyridin-3-ylethyl)amino]pyrimidin-4-yl}acetonitrile
 - (2Z)-[2-(cyclobutylamino)pyrimidin-4-yl](1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)acetonitrile
- 15 (2Z)-[2-(cycloheptylamino)-5-methylpyrimidin-4-yl](1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)acetonitrile
 - $[2\hbox{-}(cyclopentylamino) pyrimidin-4-yl] (1\hbox{-}ethyl-1 H-benzimidaz ol-2-yl) acetonitrile$
 - 1,3-dihydro-2H-benzimidazol-2-ylidene(5-methyl-2-{[3-(2-oxopyrrolidin-1-yl)propyl]amino}pyrimidin-4-yl)acetonitrile
- 20 (2Z)-(1-cyclobutyl-1,3-dihydro-2H-benzimidazol-2-ylidene)(2-{[3-(2-oxopyrrolidin-1-yl)propyl]amino}pyrimidin-4-yl)acetonitrile

- (1-ethyl-1H-benzimidazol-2-yl){2-[(2-pyridin-3-ylethyl)amino]pyrimidin-4-yl}acetonitrile
- (2Z)-(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)[2-(isobutylamino)-5-methylpyrimidin-4-yl]acetonitrile
- 5 (2Z)-(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)(2-{[2-(1H-imidazol-4-yl)ethyl]amino}pyrimidin-4-yl)acetonitrile
 - (2Z)-(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)[2-(isobutylamino)pyrimidin-4-yl]acetonitrile
 - [2-(cyclopropylamino)pyrimidin-4-yl](1-ethyl-1H-benzimidazol-2-yl)acetonitrile
- 10 [2-({2-[6-(dimethylamino)pyridin-3-yl]ethyl}amino)pyrimidin-4-yl](1-ethyl-1H-benzimidazol-2-yl)acetonitrile
 - (1-ethyl-1H-benzimidazol-2-yl)(2-{[2-(1H-1,2,4-triazol-1-yl)ethyl]amino}pyrimidin-4-yl)acetonitrile
- (2Z)-(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)(2-{[2-(1H-imidazol-4-yl)ethyl]amino}-5-methylpyrimidin-4-yl)acetonitrile
 - [2-({2-[6-(dimethylamino)pyridin-3-yl]ethyl}amino)-5-methylpyrimidin-4-yl](1-ethyl-1H-benzimidazol-2-yl)acetonitrile
 - (2Z)-[2-(cycloheptylamino)pyrimidin-4-yl](1-ethyl-1,3-dibydro-2H-benzimidazol-2-ylidene)acetonitrile
- 20 [2-(cyclopropylamino)-5-methylpyrimidin-4-yl](1-ethyl-1H-benzimidazol-2-yl)acetonitrile

WO 2005/026155 PCT/EP2004/052137

- 116 -

- (1-ethyl-1H-benzimidazol-2-yl){2-[(2-pyridin-2-ylethyl)amino]pyrimidin-4-yl}acetonitrile
- [2-(cyclopentylamino)-5-methylpyrimidin-4-yl](1,3-dihydro-2H-benzimidazol-2-ylidene)acetonitrile
- [2-(cyclohexylamino)pyrimidin-4-yl](1-ethyl-1H-benzimidazol-2-yl)acetonitrile

 (2Z)-(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)(2-{[2-(1H-indol-3-yl)ethyl]amino}-5-methylpyrimidin-4-yl)acetonitrile
 - (1-ethyl-1H-benzimidazol-2-yl){5-methyl-2-[(2-pyridin-2-ylethyl)amino]pyrimidin-4-yl}acetonitrile
- {2-[(2-ethoxyethyl)amino]pyrimidin-4-yl}(1-ethyl-1H-benzimidazol-2-yl)acetonitrile
 (1-ethyl-1H-benzimidazol-2-yl){5-methyl-2-[(1-methylbutyl)amino]pyrimidin-4-yl}acetonitrile
 - (1-ethyl-1H-benzimidazol-2-yl)[2-(methylamino) pyrimidin-4-yl] acetonitrile
 - (1-ethyl-1H-benzimidazol-2-yl)(5-methyl-2-{[2-(1H-pyrazol-1-
 - 15 yl)ethyl|amino}pyrimidin-4-yl)acetonitrile
 - 1H-benzimidazol-2-yl{5-methyl-2-[(2-pyridin-3-ylethyl)amino]pyrimidin-4-yl}acetonitrile
 - (2Z)-(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)(2-{[2-(1H-imidazol-1-yl)ethyl]amino}-5-methylpyrimidin-4-yl)acetonitrile
- 20 1H-benzimidazol-2-yl{2-[(2-pyridin-3-ylethyl)amino]pyrimidin-4-yl}acetonitrile (1-ethyl-1H-benzimidazol-2-yl){2-[(1-methylbutyl)amino]pyrimidin-4-yl}acetonitrile

- {2-[(cyclohexylmethyl)amino]-5-methylpyrimidin-4-yl}(1-ethyl-1H-benzimidazol-2-yl)acetonitrile
- 1H-benzimidazol-2-yl[2-(cyclopentylamino)pyrimidin-4-yl]acetonitrile
- (1-ethyl-1H-benzimidazol-2-yl) {6-methyl-2-[(2-pyridin-3-ylethyl)amino]pyrimidin-4-yl}acetonitrile
 - 1H-benzimidazol-2-yl[2-(cyclopropylamino)pyrimidin-4-yl]acetonitrile

10

- [2-(cyclopentylamino)-6-methylpyrimidin-4-yl](1-ethyl-1H-benzimidazol-2-yl)acetonitrile
- {2-[(cyclohexylmethyl)amino]pyrimidin-4-yl}(1-ethyl-1H-benzimidazol-2-yl)acetonitrile
- (1-ethyl-1H-benzimidazol-2-yl){6-[(2-pyridin-3-ylethyl)amino]pyrimidin-4-yl}acetonitrile
- (1-ethyl-1H-benzimidazol-2-yl){2-[(3-pyrrolidin-1-ylpropyl)amino]pyrimidin-4-yl}acetonitrile
- 15 (1-ethyl-1H-benzimidazol-2-yl)[2-(4-ethylpiperazin-1-yl)-5-methylpyrimidin-4-yl]acetonitrile
 - (1-ethyl-1H-benzimidazol-2-yl){2-[(2-furylmethyl)amino]-5-methylpyrimidin-4-yl}acetonitrile
- (2Z)-(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene) {5-methyl-2-[(1-methylpiperidin-4-yl)amino]pyrimidin-4-yl} acetonitrile
 - (2Z)-[2-(cyclohexylamino)-5-methylpyrimidin-4-yl](1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)acetonitrile

15

(2Z)-[2-(ethylamino)-5-methylpyrimidin-4-yI](1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)acetonitrile

[2-(cyclopentylamino)-5-methylpyrimidin-4-yl](1,3-diethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)acetonitrile

5 (2Z)-(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)[5-methyl-2-(piperidin-4-ylamino)pyrimidin-4-yl]acetonitrile

(2Z)-(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene) {5-methyl-2-[(2-piperidin-1-ylethyl)amino]pyrimidin-4-yl} acetonitrile

N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-4-(4-methylpiperazin-1-yl)-4-oxobutanamide

 $N-\{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene) methyl] pyrimidin-2-yl\}-4-(4-methylpiperazin-1-yl)-4-oxobutanamide$

(1R,5R,7R)-N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide

(1S,5S,7S)-N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide

(1S,4S,5S,7R)-N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-4-methyl-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide

20

(1S,4R,5S,7R)-N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-4-methyl-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide

N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}piperazine-2-carboxamide

(4S)-N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-1,3-thiazolidine-4-carboxamide

(4R)-N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-1,3-thiazolidine-4-carboxamide

N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-5-oxo-L-prolinamide

 $\label{thm:continuous} $$4$-tert-butyl 1-(9H-fluoren-9-ylmethyl) 2-[(\{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl\}amino)carbonyl]piperazine-1,4-dicarboxylate$

tert-butyl (4S)-4-[({4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}amino)carbonyl]-1,3-thiazolidine-3-carboxylate

tert-butyl (2S)-2-[({4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}amino)carbonyl]-5-oxopyrrolidine-1-carboxylate

tert-butyl (4R)-4-[({4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}amino)carbonyl]-1,3-thiazolidine-3-carboxylate

20

2-(1-acetylpiperidin-4-yl)-N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}acetamide

N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-4-methylmorpholine-2-carboxamide

5 4-acetyl-N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}morpholine-2-carboxamide

N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-4-[(4-methylpiperazin-1-yl)methyl]benzamide

tert-butyl 3-[({4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-

ylidene)methyl]-5-methylpyrimidin-2-yl}amino)carbonyl]piperidine-1-carboxylate

tert-butyl 4-[2-({4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-

ylidene)methyl]-5-methylpyrimidin-2-yl}amino)-2-oxoethyl]piperidine-1-carboxylate

N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}morpholine-2-carboxamide

N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-2-piperidin-4-ylacetamide

N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}piperidine-3-carboxamide

tert-butyl 2-[({4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-

ylidene)methy[]-5-methylpyrimidin-2-yl}amino)carbonyl]morpholine-4-carboxylate

N-[3-({4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}amino)-3-oxopropyl]benzamide

tert-butyl [2-({4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}amino)-2-oxoethyl]methylcarbamate

N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-1-methylpiperidine-3-carboxamide

5 N~1~-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-N~2~-methylglycinamide

10

15

N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}pyrrolidine-3-carboxamide

tert-butyl 3-[({4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}amino)carbonyl]pyrrolidine-1-carboxylate

(2S)-N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-2,5-dihydro-1H-pyrrole-2-carboxamide

tert-butyl (2S)-2-[({4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}amino)carbonyl]-2,5-dihydro-1H-pyrrole-1-carboxylate

N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-2-(2-methoxyphenyl)acetamide

1-acetyl-N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}piperidine-4-carboxamide

N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-1-methylpiperidine-4-carboxamide

4-amino-N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}butanamide

20

tert-butyl 4-[({4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}amino)carbonyl]piperidine-1-carboxylate

N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}piperidine-4-carboxamide

tert-butyl [4-({4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}amino)-4-oxobutyl]carbamate

N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}cyclopentanecarboxamide

N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-4-(4-methylpiperazin-1-yl)butanamide

N~1~-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-N~3~,N~3~-dimethyl-beta-alaninamide

N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-4-(dimethylamino)butanamide

15 (2Z)-(2-amino-5-methylpyrimidin-4-yl)(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)acetonitrile

 $N-\{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene) methyl]-5-methylpyrimidin-2-yl\}-2-morpholin-4-ylacetamide$

N~2~-benzyl-N~1~-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}glycinamide

N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-2-(1,1-dioxidothiomorpholin-4-yl)acetamide

WO 2005/026155 PCT/EP2004/052137

- 123 -

- N~1~-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-N~2~-formylglycinamide
- 9. A benzimidazole acetonitrile according to any of the preceding claims for use as a medicament.
- 5 10. Use of a benzimidazole acetonitrile according to any of claims 1 to 8 in the preparation of a medicament for the prevention and/or treatment of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type II, inadequate glucose tolerance, insulin resistance, obesity, polycystic ovary syndrome (PCOS).
- 10 11. Use of an benzimidazole acctonitrile according to claim 9 wherein the disease is diabetes type II.
 - 12. A pharmaceutical composition containing a benzimidazole acetonitrile according to any of the claims 1 to 8 and a pharmaceutically acceptable carrier, diluent or excipient thereof.
- 13. A composition according to claim 12, further comprising at least one supplementary drug selected from the group consisting of insulin, aldose reductase inhibitors, alphaglucosidase inhibitors, sulfonyl urea agents, biguanides, thiazolidines, PPARs agonists, GSK-3 inhibitors.
- Composition according to claim 13 wherein said supplementary drug is selected from the group consisting of a rapid acting insulin, an intermediate acting insulin, a long acting insulin, a combination of intermediate and rapid acting insulins, Minalrestat, Tolrestat, Sorbinil, Methosorbinil, Zopolrestat, Epalrestat, Zenarestat, Imirestat, Ponalrestat, ONO-2235, GP-1447, CT-112, BAL-ARI 8, AD-5467, ZD5522, M-16209, NZ-314, M-79175, SPR-210, ADN 138, or SNK-860, Miglitol, Acarbose, Glipizide, Glyburide, Chlorpropamide, Tolbutamide, Tolazamide, or Glimepriride.

15. A method of preparing a benzimidazole acetonitrile of formula (I) according to any of the claims 1 to 8, comprising the following step:

wherein R1, R2, G, L are as above described.

5 16. A method of preparing a benzimidazole acetonitrile of formula (I) according to any of the claims 1 to 8, comprising the following step:

17. A method according to claim 15 or 16, comprising the following steps:

wherein R¹, R³ and R⁴ are as above defined.

17. Λ method according to claim 15, comprising the following steps:

- wherein R¹, R³ and R⁴ are as above defined.
 - 18. An intermediate compound of formula (II), selected from the group consisting of: 1,3-benzimidazol-2(3H)-ylidene(2-chloro-6-methylpyrimidin-4-yl)acetonitrile 1,3-benzimidazol -2(3H)-ylidene(2-chloro-6-methylpyrimidin-4-yl)acetonitrile 1,3-benzimidazol -2(3H)-ylidene(6-chloropyrimidin-4-yl)acetonitrile